Cutler Group’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-400
Closed -$21K 6401
2021
Q1
$21K Buy
+400
New +$23K ﹤0.01% 3181
2018
Q2
Sell
-3,311
Closed -$18K 4938
2018
Q1
$18K Sell
3,311
-5,500
-62% -$34K ﹤0.01% 2378
2017
Q4
$57K Sell
8,811
-31,283
-78% -$233K ﹤0.01% 1770
2017
Q3
$351K Sell
40,094
-14,513
-27% -$118K 0.01% 842
2017
Q2
$454K Buy
54,607
+26,815
+96% +$219K 0.02% 744
2017
Q1
$255K Buy
27,792
+15,465
+125% +$127K 0.01% 1028
2016
Q4
$95K Buy
12,327
+6,351
+106% +$47.5K ﹤0.01% 1954
2016
Q3
$45K Buy
5,976
+1,008
+20% +$5.7K ﹤0.01% 2570
2016
Q2
$24K Buy
+4,968
New +$26.6K ﹤0.01% 3169

Other funds holding VCYT

Cutler Group's VCYT Position: Q2 2021 in Review

Cutler Group sold out of Veracyte (VCYT) in Q2 2021, closing a stake of 400 shares — an estimated $21K sold.

Cutler Group first reported a position in VCYT in Q2 2016 and held it in 9 quarters. The position peaked at $454K in Q2 2017. 214 funds tracked by Wall St. Rank hold VCYT as of Q2 2021.

  • Cutler Group reported no remaining Veracyte position as of Q2 2021 after selling out during the quarter.
  • Cutler Group sold 400 Veracyte shares in Q2 2021, an estimated $21K.
  • Cutler Group first reported a position in Veracyte in Q2 2016 and held it in 9 quarters.
  • Cutler Group's Veracyte position peaked at $454K in Q2 2017.
  • 214 funds tracked by Wall St. Rank held Veracyte as of Q2 2021.

Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.